Shares of Novavax up 11% after positive Phase IIb flu vax results; Scientists turn to DNA nanotechnology for new synthetic vaccines;

 @AlisonBFierce: Sanofi Pasteur successfully combats three of four virus serotypes of dengue in Thailand. Article | Follow @AlisonBFierce

> A new study found that people infected with HIV-2 and then later HIV-1 appear better equipped to fight off the virus. Story

> Scientists have turned to DNA nanotechnology to develop a new class of synthetic vaccines. Article

> A new public-private partnership, the Collaboration for HIV/AIDS Immunological Therapy (CHAIT Initiative), will work to combat HIV/AIDS. Release

> Shares of Novavax ($NVAX) climbed 11% Wednesday after the company released positive results from a Phase IIb clinical trial for its seasonal flu vax. News

> The Indiana State Department of Health unveiled a tool that makes vaccination records available to patients online. Item

> Vaxil BioTherapeutics made its debut on the Tel Aviv Stock Exchange through a merger with Sheldonco. Story (sub. req.)

And Finally... A needle-free flu vaccine will be offered to everyone in the U.K. between the ages of 2 and 17. More

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.